TRP'ing up chronic kidney disease

See allHide authors and affiliations

Science  08 Dec 2017:
Vol. 358, Issue 6368, pp. 1256-1257
DOI: 10.1126/science.aar3572

You are currently viewing the summary.

View Full Text

Log in to view the full text

Log in through your institution

Log in through your institution


Chronic kidney disease (CKD) describes a permanent and considerable loss of kidney function, which affects approximately 1 in 10 people worldwide (1). It is associated with increased risk of end-stage renal disease (ESRD), a condition that requires kidney transplantation or dialysis. Because the major causes of CKD are obesity, hypertension, and diabetes, the population at risk continues to grow (2). New therapies that can prevent or slow progression of disease are desperately needed. On page 1332 of this issue, Zhou et al. (3) show that pharmacological inhibition of a calcium channel, transient receptor potential canonical-5 (TRPC5), can delay progression of kidney disease due to hypertension.